{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:44:30Z","timestamp":1743500670906,"version":"3.37.3"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1124\/dmd.113.054346","type":"journal-article","created":{"date-parts":[[2013,12,25]],"date-time":"2013-12-25T02:48:31Z","timestamp":1387939711000},"page":"323-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["An Ethinyl Estradiol-Levonorgestrel Containing Oral Contraceptive Does Not Alter Cytochrome P4502C9 In Vivo Activity"],"prefix":"10.1016","volume":"42","author":[{"given":"Ganesh","family":"Cherala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Maslen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.054346_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/mgme.2000.3103","article-title":"Carrier frequency of the common mutation IVS8-1G>C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome","volume":"72","author":"Battaile","year":"2001","journal-title":"Mol Genet Metab"},{"key":"10.1124\/dmd.113.054346_bib2","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1124\/dmd.109.026997","article-title":"Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro","volume":"37","author":"Chang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.054346_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/AOG.0b013e31820095a2","article-title":"Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen","volume":"117","author":"Dinger","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1124\/dmd.113.054346_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2125.2012.04209.x","article-title":"Effect of the ethinylestradiol\/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women","volume":"74","author":"Edelman","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.054346_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2012.10.008","article-title":"Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users","volume":"87","author":"Edelman","year":"2013","journal-title":"Contraception"},{"key":"10.1124\/dmd.113.054346_bib6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/bmj.321.7273.1382","article-title":"Drug Points: Apparent interaction between warfarin and levonorgestrel used for emergency contraception","volume":"321","author":"Ellison","year":"2000","journal-title":"BMJ"},{"key":"10.1124\/dmd.113.054346_bib7","unstructured":"European Medicines Agency (2010). Guideline on the investigation of bioequivalence [cited DATE]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf. Accessed on 8\/16\/2013."},{"key":"10.1124\/dmd.113.054346_bib8","unstructured":"Gainer E (2003) In vitro studies, post-marketing data do not corroborate levonorgestrel-warfarin interaction [cited DATE]. Available from: http:\/\/www.bmj.com\/content\/321\/7273\/1382?tab=responses"},{"key":"10.1124\/dmd.113.054346_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.054346_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1309\/76QPHQ892F17QKNC","article-title":"Detection and identification of cytochrome P-450 2C9 alleles *1, *2, and *3 by high-resolution melting curve analysis of PCR amplicons","volume":"125","author":"Hill","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1124\/dmd.113.054346_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00228-004-0754-z","article-title":"Cytochrome P450 2C9 phenotyping using low-dose tolbutamide","volume":"60","author":"Jetter","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.054346_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1600-0773.2003.t01-1-930202_93_2.x","article-title":"A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes","volume":"93","author":"Laine","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.054346_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.054346_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/dmd.32.5.484","article-title":"The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype","volume":"32","author":"Sandberg","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.054346_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/humrep\/deg090","article-title":"Differences in the use of combined oral contraceptives amongst women with and without acne","volume":"18","author":"Seaman","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1124\/dmd.113.054346_bib16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/0091270005280851","article-title":"Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail","volume":"45","author":"Shelepova","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.054346_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2006.11.009","article-title":"The cost of unintended pregnancy in the United States","volume":"75","author":"Trussell","year":"2007","journal-title":"Contraception"},{"year":"2003","series-title":"Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products \u2013 General Considerations","key":"10.1124\/dmd.113.054346_bib18"},{"key":"10.1124\/dmd.113.054346_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2125.2002.01646.x","article-title":"Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity","volume":"54","author":"Yasar","year":"2002","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624098416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624098416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.054346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:12:39Z","timestamp":1739905959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624098416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0090955624098416"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.054346","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Ethinyl Estradiol-Levonorgestrel Containing Oral Contraceptive Does Not Alter Cytochrome P4502C9 In Vivo Activity","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.054346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}